Atomic AI, a biotech company focusing on RNA drug discovery, launched with a $35 million series A financing round.
The company uses artificial intelligence to generate RNA datasets that can be used for drug discovery. Previously, the company had raised $7 million in a seed financing round, according to a Jan. 25 Atomic AI news release.
Playground Global led the financing.
"To create effective and safer small molecules against undruggable diseases, there is a significant need to develop tools that can accurately predict 3D RNA structures," Atomic AI founder and CEO Raphael Townshend, PhD, said. "Atomic AI is oriented at the cutting edge of AI, RNA, and structural biology. We are creating an entirely new field of drug discovery."